Pre-made Urelumab biosimilar ( Whole mAb, anti-TNFRSF9 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-604
Anti-TNFRSF9 therapeutic antibody (Pre-made Urelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF9 therapeutic antibody (Pre-made Urelumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6mhr:AB:DE|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex|
|Conditions Active||Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma|
|Conditions Discontinued||Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer|
|Development Tech||Medarex UltiMAb Mouse|